We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Phibro Animal Health Stock Climbs 90.9% in a Year: What's Driving It?
Read MoreHide Full Article
Key Takeaways
Phibro Animal Health stock has climbed 90.9% this year, far outperforming its industry and the market.
PAHC vaccine sales rose 25% in fiscal Q1, driven by poultry growth in Latin America and higher global demand.
PAHC is expanding globally, with EMEA sales up 44.4% and Asia Pacific sales surging 101.1% in fiscal Q1.
Phibro Animal Health (PAHC - Free Report) shares have surged 90.9% in the past year, demonstrating impressive momentum. The performance has outpaced the industry’s 5.4% decline and the S&P 500 composite’s 19.6% gain.
Sporting a Zacks Rank #1 (Strong Buy) at present, the renowned animal health and mineral nutrition company is gaining from the ongoing momentum of its Animal Health portfolio. The company’s vaccine business continues to prosper, while its growing presence in the emerging markets bodes well for the stock.
New Jersey-based Phibro markets approximately 800 product lines across roughly 90 countries for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Phibro’s operations presently center on the livestock sector. Additionally, it is investing in developing products for the companion animal sector.
What’s Behind PAHC’s Surge?
The rally in the company’s share price can be linked to the sustained traction in the Vaccine business. In the first quarter of fiscal 2026, net sales of vaccines increased 25% year over year, primarily driven by continued growth of poultry products in Latin America and higher international demand.
Recently, Phibro began operations at a new vaccine production facility in Guarulhos, Brazil, that manufactures and markets autogenous vaccines against animal diseases for swine, poultry and aquaculture. The company also launched new commercial vaccines and looks forward to bringing additional vaccines to the Americas. Management highlighted vaccines as a key growth driver heading into fiscal 2026, supported by expanding capacity and sustained global demand.
Additionally, Phibro’s established sales, marketing and distribution network in approximately 90 countries provides it with ample scope to take advantage of global growth opportunities.
Outside the United States, Phibro’s global footprint extends to key high-growth regions, including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries and South Africa and other countries in Africa. In the first quarter of fiscal 2026, net sales in Europe, the Middle East and Africa increased 44.4%, while Asia Pacific sales jumped 101.1%.
Meanwhile, Phibro’s solid financial health is another plus. As of the end of the first quarter of fiscal 2026, Phibro’s total cash and short-term investments were $85.3 million. The company has pretty good solvency reflected through its low short-term-payable debt of $18 million on its balance sheet.
Image Source: Zacks Investment Research
Concern for PAHC
Phibro conducts operations globally, which entails transactions in a variety of currencies. The company is exposed to changes in the cost of goods sold resulting from currency movements and may not be able to adjust its selling prices to offset these impacts. Foreign currency losses, net for the three months ended Sept. 30, 2025, were $2.9 million compared with a loss of $0.4 million in the year-ago period.
A Glance at PAHC’s Estimates
The Zacks Consensus Estimate for Phibro’s fiscal 2026 and 2027 earnings per share (EPS) is expected to increase 32.1% and 6.3%, respectively, year over year to $2.76 and $2.94. In the past 30 days, the Zacks Consensus Estimate for the company's fiscal 2026 EPS has remained unchanged.
Revenues for fiscal 2026 are projected to grow 13.1% to $1.47 billion, while those for fiscal 2027 are expected to reach $1.51 billion, implying a 2.9% increase.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Boston Scientific (BSX - Free Report) , Charles River Laboratories International (CRL - Free Report) and Prestige Consumer (PBH - Free Report) .
BSX has an earnings yield of 3.7% compared with the industry’s 2.8% yield. Shares of the company have surged 92.1% over the past year against the industry’s 3.8% decline. BSX’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 7.4%.
Charles River Laboratories, currently carrying a Zacks Rank #2, has an earnings yield of 5% compared with the industry’s 4.1% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 12.4%. CRL shares have surged 14.7% compared with the industry’s 6.8% growth over the past year.
Prestige Consumer, currently carrying a Zacks Rank #2, has an earnings yield of 7% compared with the industry’s 2.8% yield. Shares of the company have jumped 13.9% compared with the industry’s 5.2% growth. PBH’s earnings surpassed estimates in three of the trailing four quarters and missed in one, with the average surprise being 2.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Phibro Animal Health Stock Climbs 90.9% in a Year: What's Driving It?
Key Takeaways
Phibro Animal Health (PAHC - Free Report) shares have surged 90.9% in the past year, demonstrating impressive momentum. The performance has outpaced the industry’s 5.4% decline and the S&P 500 composite’s 19.6% gain.
Sporting a Zacks Rank #1 (Strong Buy) at present, the renowned animal health and mineral nutrition company is gaining from the ongoing momentum of its Animal Health portfolio. The company’s vaccine business continues to prosper, while its growing presence in the emerging markets bodes well for the stock.
New Jersey-based Phibro markets approximately 800 product lines across roughly 90 countries for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. The company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. Phibro’s operations presently center on the livestock sector. Additionally, it is investing in developing products for the companion animal sector.
What’s Behind PAHC’s Surge?
The rally in the company’s share price can be linked to the sustained traction in the Vaccine business. In the first quarter of fiscal 2026, net sales of vaccines increased 25% year over year, primarily driven by continued growth of poultry products in Latin America and higher international demand.
Recently, Phibro began operations at a new vaccine production facility in Guarulhos, Brazil, that manufactures and markets autogenous vaccines against animal diseases for swine, poultry and aquaculture. The company also launched new commercial vaccines and looks forward to bringing additional vaccines to the Americas. Management highlighted vaccines as a key growth driver heading into fiscal 2026, supported by expanding capacity and sustained global demand.
Additionally, Phibro’s established sales, marketing and distribution network in approximately 90 countries provides it with ample scope to take advantage of global growth opportunities.
Outside the United States, Phibro’s global footprint extends to key high-growth regions, including Brazil and other countries in South America, China, India and Southeast Asia, Mexico, Turkey, Australia, Canada, Poland and other Eastern European countries and South Africa and other countries in Africa. In the first quarter of fiscal 2026, net sales in Europe, the Middle East and Africa increased 44.4%, while Asia Pacific sales jumped 101.1%.
Meanwhile, Phibro’s solid financial health is another plus. As of the end of the first quarter of fiscal 2026, Phibro’s total cash and short-term investments were $85.3 million. The company has pretty good solvency reflected through its low short-term-payable debt of $18 million on its balance sheet.
Image Source: Zacks Investment Research
Concern for PAHC
Phibro conducts operations globally, which entails transactions in a variety of currencies. The company is exposed to changes in the cost of goods sold resulting from currency movements and may not be able to adjust its selling prices to offset these impacts. Foreign currency losses, net for the three months ended Sept. 30, 2025, were $2.9 million compared with a loss of $0.4 million in the year-ago period.
A Glance at PAHC’s Estimates
The Zacks Consensus Estimate for Phibro’s fiscal 2026 and 2027 earnings per share (EPS) is expected to increase 32.1% and 6.3%, respectively, year over year to $2.76 and $2.94. In the past 30 days, the Zacks Consensus Estimate for the company's fiscal 2026 EPS has remained unchanged.
Revenues for fiscal 2026 are projected to grow 13.1% to $1.47 billion, while those for fiscal 2027 are expected to reach $1.51 billion, implying a 2.9% increase.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Boston Scientific (BSX - Free Report) , Charles River Laboratories International (CRL - Free Report) and Prestige Consumer (PBH - Free Report) .
BSX has an earnings yield of 3.7% compared with the industry’s 2.8% yield. Shares of the company have surged 92.1% over the past year against the industry’s 3.8% decline. BSX’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 7.4%.
BSX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Charles River Laboratories, currently carrying a Zacks Rank #2, has an earnings yield of 5% compared with the industry’s 4.1% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 12.4%. CRL shares have surged 14.7% compared with the industry’s 6.8% growth over the past year.
Prestige Consumer, currently carrying a Zacks Rank #2, has an earnings yield of 7% compared with the industry’s 2.8% yield. Shares of the company have jumped 13.9% compared with the industry’s 5.2% growth. PBH’s earnings surpassed estimates in three of the trailing four quarters and missed in one, with the average surprise being 2.8%.